Evidence map›Paper›PMID 35133567›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2022

A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing.

Claire Snyder, Susan M Hannum, Sharon White, Amanda Montanari, Dara Ikejiani, Benjamin Smith, Amanda Blackford, Elissa Thorner, Katherine C Smith, Michael A Carducci and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Claire SnyderJohns Hopkins University School of Medicine, Baltimore, MD, USA. csnyder@jhu.edu.ORCID http://orcid.org/0000-0001-8952-4561
Susan M HannumJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Sharon WhiteSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Amanda MontanariSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Dara IkejianiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Benjamin SmithJohns Hopkins Health System, Baltimore, MD, USA.
Amanda BlackfordJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Elissa ThornerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Katherine C SmithSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Michael A CarducciJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Vered StearnsJohns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4018-4708
Karen Lisa SmithJohns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6687-0119
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973NCI NIH HHS P30CA006973
6 · The paper itself

Abstract

purposePRO-cision medicine refers to personalizing care using patient-reported outcomes (PROs). We developed and feasibility-tested a PRO-cision Medicine remote PRO monitoring intervention designed to identify symptoms and reduce the frequency of routine in-person visits.

methodsWe conducted focus groups and one-on-one interviews with metastatic breast (n = 15) and prostate (n = 15) cancer patients and clinicians (n = 10) to elicit their perspectives on a PRO-cision Medicine intervention's design, value, and concerns. We then feasibility-tested the intervention in 24 patients with metastatic breast cancer over 6-months. We obtained feedback via end-of-study surveys (patients) and interviews (clinicians).

resultsFocus group and interview participants reported that remote PRO symptom reporting could alert clinicians to issues and avoid unneeded/unwanted visits. However, some patients did not perceive avoiding visits as beneficial. Clinicians were concerned about workflow. In the feasibility-test, 24/236 screened patients (10%) enrolled. Many patients were already being seen less frequently than monthly (n = 97) or clinicians did not feel comfortable seeing them less frequently than monthly (n = 31). Over the 6-month study, there were 75 total alerts from 392 PRO symptom assessments (average 0.19 alert/assessment). Patients had an average of 4 in-person visits (vs. expected 6.5 without the intervention). Patients (n = 19/24) reported high support on the end-of-study survey, with more than 80% agreeing with positive statements about the intervention. Clinician end-of-study interviews (n = 11/14) suggested that PRO symptom monitoring be added to clinic visits, rather than replacing them, and noted the increasing role of telemedicine.

conclusionsFuture research should explore combining remote PRO symptom monitoring with telemedicine and in-person visits.

Indexed as

Breast NeoplasmsQuality of LifeFeasibility StudiesHumansMalePatient Reported Outcome MeasuresSurveys and QuestionnairesBreast cancerClinical carePatient-reported outcomesProstate cancerSymptom monitoring

Identifiers

PMID35133567
PMCPMC9253074
OpenAlexW4210834556

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.